Onco-Summaries: Daily Oncology Updates at a Glance
13/09/2026
First-time outcomes from the failed Ph3 EVOKE-03 study of sacituzumab govitecan-hziy+ pembro in Tx naive PD-L1 ≥50% NSCLC pts presented at WCLC'26 (abstract #PL02.06; Ref)
The first reported efficacy and safety outcomes from the Ph3 KEYNOTE-D46/EVOKE-03 trial of Gilead's sacituzumab govitecan-hziy (SG; TROP2 ADC) + Merck & Co/MSD's pembrolizumab (Keytruda; anti-PD-1) in PD-L1 TPS ≥50% Tx-naive was presented in a Presidential Symposium at WCLC 2026
At median follow-up of 14.7 mos, following results were observed in evaluable pts in the SG + pembro (n=311) vs pembro (n=309) arms:
ORR: 55.6% vs 43.7%
mDOR: 21.4 mos vs 21.3 mos
mPFS: 11.8 mos vs 7.7 mos; HR 0.81 (p=0.0252)
mOS: 21.5 mos vs 22.8 mos; HR 1.07 (p=0.7155)
Gr≥3 TEAEs: 73.6% vs 45.0%
While efficacy parameters were comparable between the two, SG + pembro arm had much higher TEAEs, a trend typically seen in ADC assets.
Despite a numerical improvement in PFS and a higher response rate, SG + pembro did not meet statistical significance for PFS compared with pembro mono in pts with untreated PD-L1-high metastatic . Overall survival also did not meet statistical significance at the interim analysis.
Comments